Results 61 to 70 of about 8,317,164 (175)

A reassessment of soluble urokinase-type plasminogen activator receptor in glomerular disease [PDF]

Kidney International, 2015
It has been suggested that soluble urokinase receptor (suPAR) is a causative circulating factor for and a biomarker of focal and segmental glomerulosclerosis (FSGS). Here we undertook validation of these assumptions in both mouse and human models. Injection of recombinant suPAR in wild-type mice did not induce proteinuria within 24 h.
Spinale, Joann M., Mariani, Laura H., Kapoor, Shiv, Zhang, Jidong, Weyant, Robert, Song, Peter X., Wong, Hetty N., Troost, Jonathan P., Gadegbeku, Crystal A., Gipson, Debbie S., Kretzler, Matthias, Nihalani, Deepak, Holzman, Lawrence B.   +12 more
openaire   +2 more sources

Prevention of Early Onset of Breast Cancer With Ashwagandha

Molecular Carcinogenesis, EarlyView.
ABSTRACT Prevention of breast cancer is feasible because many risk factors for this malignancy are known (e.g., family history, reproductive factors, etc.). Medicinal plants and/or their bioactive phytochemicals are attractive for the prevention of early onset of breast cancer due to their generally favorable safety profile.
Eun‐Ryeong Hahm, Su‐Hyeong Kim, Shivendra V. Singh   +2 more
wiley   +1 more source

The Receptor for Urokinase-type Plasminogen Activator Is Not Essential for Mouse Development or Fertility [PDF]

Journal of Biological Chemistry, 1995
The urokinase-type plasminogen activator receptor (uPAR) gene was disrupted in mice in order to explore the role of cell surface-associated plasminogen activation in development and hemostasis. Homozygous, uPAR-/- mice were born and survived to adulthood with no overt phenotypic abnormalities.
T H, Bugge, T T, Suh, M J, Flick, C C, Daugherty, J, Rømer, H, Solberg, V, Ellis, K, Danø, J L, Degen   +8 more
openaire   +2 more sources

Bioactive Natural Products in Cardiovascular Disease: Focus on Thrombotic Events

Phytotherapy Research, EarlyView.
An overview of the role of natural products (NP) in cardiovascular disease prevention, highlighting key mechanisms of action: including antiplatelet, antithrombotic, anti‐inflammatory, and antioxidant effects. Additionally, it illustrates the integration of diet–drug interactions, nutritional epigenetics, and the role of artificial intelligence in ...
Maria Nektaria Magkoulia, Despoina Pantazi   +1 more
wiley   +1 more source

Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications

Frontiers in Oncology, 2018
The plasminogen activator (PA) system is an extracellular proteolytic enzyme system associated with various physiological and pathophysiological processes.
Niaz Mahmood, Catalin Mihalcioiu, Shafaat A. Rabbani, Shafaat A. Rabbani   +3 more
doaj   +1 more source

N-Alkylisatin-Loaded Liposomes Target the Urokinase Plasminogen Activator System in Breast Cancer

Pharmaceutics, 2020
The urokinase plasminogen activator and its receptor (uPA/uPAR) are biomarkers for metastasis, especially in triple-negative breast cancer. We prepared anti-mitotic N-alkylisatin (N-AI)-loaded liposomes functionalized with the uPA/uPAR targeting ligand ...
Lisa Belfiore, Darren N. Saunders, Marie Ranson, Kara L. Vine   +3 more
doaj   +1 more source

Carbon dots as a smart nanoplatform for the blood‐brain barrier penetration and ischemic stroke therapy

Responsive Materials, EarlyView.
This review presents the structure and transport routes of the blood‐brain barrier, summarizes the ischemic stroke pathophysiological cascade, and discusses the BBB‐crossing mechanisms and multitarget therapeutic effects of carbon dots, demonstrating their promising theranostic potential for ischemic stroke.
Yanhan Huang, Xuan Hou, Haiping Zhao, Qi Kong, Xiayan Wang, Xiaokun Geng, Zaicheng Sun   +6 more
wiley   +1 more source

Urokinase Plasminogen Activator

, 2016
The urokinase plasminogen activator system (uPAS) is an essential mechanism in a wide variety of biological processes such as fibrinoloysis, inflammation, atherosclerotic plaque formation, matrix remodeling during wound healing, tumor invasion ...
Ali Salajegheh, Salajegheh, Ali
core   +1 more source

Multimodal therapy for synergic inhibition of tumour cell invasion and tumour-induced angiogenesis [PDF]

, 2010
Background: Squamous cell carcinoma of the head and neck (SCCHN) are highly invasive tumours with frequent local and distant recurrence. Metastasis formation requires degradation of the extracellular matrix, which is fulfilled by membrane-associated ...
Olivier Gires, Muehlenweg Bernd, Pamela Zengel, Muehlenweg, Bernd, Gires, Olivier, Ramp, D., Gires, O., Alexander Berghaus, Gires Olivier, Mack, Brigitte, Zengel, Pamela, Zahler, Stefan, Muehlenweg, B., Diana Ramp, Stefan Zahler, Mack, B., Bernd Muehlenweg, Zahler, S., Berghaus Alexander, Mack Brigitte, Zengel, P., Suna Schmitz, Berghaus, Alexander, Schmitz, Suna, Schmitz, S., Ramp, Diana, Schmitz Suna, Zahler Stefan, Zengel Pamela, Brigitte Mack, Ramp Diana, Berghaus, A.   +31 more
core   +2 more sources

Current Advances of Treatments, Therapeutic Targets, Biomarkers, Novel Drugs, and Machine Learning for Hypopharyngeal Squamous Cell Carcinoma

World Journal of Otorhinolaryngology - Head and Neck Surgery, EarlyView.
ABSTRACT Hypopharyngeal squamous cell carcinoma (HSCC) is an aggressive subtype of head and neck squamous cell carcinoma with insidious onset, early metastasis, and dismal prognosis. Conventional multimodal therapy achieves limited survival benefit, highlighting an urgent need for refined precision strategies.
Ce Li, Rui Guan, Rui‐Jie Jiao, Zhi‐Jie Bi, Yang Fu, Yin Wang, Chen‐Yang Xu, Ye Qian, Ran Wei, Sheng‐Da Cao, Wen‐Ming Li, Dong‐Min Wei, Da‐Peng Lei   +12 more
wiley   +1 more source